ZBD | $40,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026)
Cambrian BioPharma
United States
- New York, New York
- 26/10/2021
- Series C
- $100,000,000
Cambrian BioPharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.
As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.
- Industry Biotechnology Research
- Website https://www.cambrianbio.com/
- LinkedIn https://www.linkedin.com/company/cambrianbio/about/
Related People
James Peyer, PhDFounder
United States -
New York City Metropolitan Area
As Founder and CEO of Cambrian Bio, a Distributed Drug Development Company (or a "DisCo" as we like to call it), I’m focused on developing therapeutics targeting the biological drivers of aging. Cambrian builds, directs, operates, and finances a pipeline of therapeutics. I founded the company to translate laboratory breakthroughs in the extension of healthy lifespan into the clinic, because the world is entering a revolution in medical research that will change our relationship with medicines from REactive to PROactive. Learn more: www.cambrianbio.com
Before Cambrian, I started Apollo Ventures, the first company builder in Longevity Therapeutics, where I was founder, investor, and CEO of multiple companies. I did my PhD with a focus on blood stem cell biology as a National Science Foundation Fellow at UT Southwestern.
Cubby | $63,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Cork Protocol | $5,500,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)
Mendra | $82,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
Antidote Legal | $5,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)